Cargando…

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells

Inhibition of the PI3K (phosphoinositide 3-kinase)/Akt/mTORC1 (mammalian target of rapamycin complex 1) and Ras/MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase]/ERK pathways for cancer therapy has been pursued for over a decade with limited success. Em...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuen, Hiu-Fung, Abramczyk, Olga, Montgomery, Grant, Chan, Ka-Kui, Huang, Yu-Han, Sasazuki, Takehiko, Shirasawa, Senji, Gopesh, Srivastava, Chan, Kwok-Wah, Fennell, Dean, Janne, Pasi, El-Tanani, Mohamed, Murray, James T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2012
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392104/ https://www.ncbi.nlm.nih.gov/pubmed/22668349 http://dx.doi.org/10.1042/BSR20120050

Ejemplares similares

BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study
por: Makrodouli, Eleni, et al.
Publicado: (2011)

Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase()()
por: Toda, Kosuke, et al.
Publicado: (2016)

ZFAT is essential for endothelial cell assembly and the branch point formation of capillary-like structures in an angiogenesis model
por: Yoshida, Yasuhiro, et al.
Publicado: (2010)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

In vitro and clinical data analysis of Osteopontin as a prognostic indicator in colorectal cancer
por: Wei, Ran, et al.
Publicado: (2018)

Altered Energy Homeostasis and Resistance to Diet-Induced Obesity in KRAP-Deficient Mice
por: Fujimoto, Takahiro, et al.
Publicado: (2009)

ZFAT is a critical molecule for cell survival in mouse embryonic fibroblasts
por: Doi, Keiko, et al.
Publicado: (2010)

Ran GTPase promotes cancer progression via Met receptor-mediated downstream signaling
por: Yuen, Hiu-Fung, et al.
Publicado: (2016)

Targeted disruption of the K-Ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis
por: Allgayer, H, et al.
Publicado: (1999)

Zfat-Deficiency Results in a Loss of CD3ζ Phosphorylation with Dysregulation of ERK and Egr Activities Leading to Impaired Positive Selection
por: Ogawa, Masahiro, et al.
Publicado: (2013)

Solution structures of the DNA-binding domains of immune-related zinc-finger protein ZFAT
por: Tochio, Naoya, et al.
Publicado: (2015)

p120RasGAP Is a Mediator of Rho Pathway Activation and Tumorigenicity in the DLD1 Colorectal Cancer Cell Line
por: Organ, Shawna L., et al.
Publicado: (2014)

CD133 in brain tumor: the prognostic factor
por: Li, Bin, et al.
Publicado: (2016)

Wnt–β-catenin–Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer
por: Ravindranath, A, et al.
Publicado: (2011)

Identification of KRAP-expressing cells and the functional relevance of KRAP to the subcellular localization of IP(3)R in the stomach and kidney
por: FUJIMOTO, TAKAHIRO, et al.
Publicado: (2012)

Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer
por: Wong, Janet P.C., et al.
Publicado: (2017)

Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1
por: Kandasamy, Palanivel, et al.
Publicado: (2021)

Oncogenic drivers and mitochondrial dependency
por: Alvarez-Calderon, Francesca, et al.
Publicado: (2015)

The long tail of oncogenic drivers in prostate cancer
por: Armenia, Joshua, et al.
Publicado: (2018)

Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90
por: Ernst, Anne, et al.
Publicado: (2020)

Cytoplasmic Forkhead Box M1 (FoxM1) in Esophageal Squamous Cell Carcinoma Significantly Correlates with Pathological Disease Stage
por: Hui, Marco K. C., et al.
Publicado: (2011)

Oncogenic driver mutations in lung cancer
por: Luo, Susan Y, et al.
Publicado: (2013)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

CD137L, a driver of harmful inflammation in the nervous system
por: Wong, Hiu Yi, et al.
Publicado: (2023)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

In Hyperthermia Increased ERK and WNT Signaling Suppress Colorectal Cancer Cell Growth
por: Bordonaro, Michael, et al.
Publicado: (2016)

Oncogenic Viruses as Entropic Drivers of Cancer Evolution
por: Tempera, Italo, et al.
Publicado: (2021)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway
por: Yoshioka, Ema, et al.
Publicado: (2018)

PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK
por: Cho, Eunice, et al.
Publicado: (2021)

Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma
por: Hui, Marco K. C., et al.
Publicado: (2012)

Death domain–associated protein DAXX regulates noncoding RNA transcription at the centromere through the transcription regulator ZFAT
por: Ishikura, Shuhei, et al.
Publicado: (2022)

Mek1/2 Gene Dosage Determines Tissue Response to Oncogenic Ras Signaling in the Skin
por: Scholl, F A, et al.
Publicado: (2009)

The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway
por: Ogishima, Juri, et al.
Publicado: (2018)

MEK/ERK‐mediated oncogenic signals promote secretion of extracellular vesicles by controlling lysosome function
por: Hikita, Tomoya, et al.
Publicado: (2022)

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
por: Naramura, Mayumi, et al.
Publicado: (2011)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

Bcl-x(L) is an oncogenic driver in colorectal cancer
por: Scherr, Anna-Lena, et al.
Publicado: (2016)

Ribosomal proteins: a novel class of oncogenic drivers
por: Sulima, Sergey O., et al.
Publicado: (2017)

Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors
por: Zhang, Runjiao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9bhlar3r7qd1rvo2k3g4qdosm2